CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.
Clinical Trials
Intralesional Therapy for Melanoma Effective, May Have Systemic Activity
CHICAGO — Preoperative intralesional treatment with a dual antibody-cytokine fusion significantly improved relapse-free survival (RFS) in locally advanced melanoma versus surgery alone, a randomized trial showed.
Practice-Changing Results From the NADINA Trial
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses findings of an investigator-initiated phase III trial showing that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival in patients with macroscopic, resectable stage III melanoma compared with adjuvant nivolumab (LBA2)
Neoadjuvant Nivolumab/Ipilimumab New Standard of Care for Stage III Melanoma
Neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) followed by therapeutic lymph node dissection (TLND) and response-driven adjuvant therapy reduced the risk of progression, recurrence, or death by 68% compared with TLND and adjuvant nivolumab alone for patients with macroscopic stage III node-positive melanoma, according to findings from the phase 3 NADINA study presented at the 2024 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine.